|Dr. Manuel C. Aivado||Pres, CEO & Director||674.13k||N/A||1970|
|Dr. Vojislav Vukovic M.D., Ph.D.||Sr. VP & Chief Medical Officer||536.58k||N/A||1967|
|Mr. Richard J. Wanstall||VP of Fin. & Operations, Principal Financial Officer and Principal Accounting Officer||N/A||N/A||1968|
|Dr. D. Allen Annis Ph.D.||Sr. VP of Research||N/A||N/A||1973|
|Ms. Kathryn J. Gregory MBA||Sr. VP & Chief Bus. Officer||N/A||N/A||1962|
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of stabilized cell-permeating alpha-helical peptides in the oncology and other therapeutic areas in the United States. The company's lead product candidate is ALRN-6924, a cell-permeating peptide, which is in Phase 2a clinical trial for the treatment of advanced solid tumors; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS. It also develops next generation wild type p53 reactivator. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is headquartered in Watertown, Massachusetts.
Aileron Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.